Candel Therapeutics (CADL) Other Accumulated Expenses (2020 - 2025)

Candel Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $464000.0 for Q4 2025.

• In Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $464000.0; the TTM figure through Dec 2025 stood at $464000.0 (changed N/A YoY), while the FY2025 annual figure was $464000.0, changed N/A from the prior year.
• Other Accumulated Expenses came in at $464000.0 for Q4 2025 at Candel Therapeutics, up from $55000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $464000.0 in Q4 2025 to a low of $31000.0 in Q3 2022.
• A 4-year average of $177600.0 and a median of $94000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses tumbled 86.46% in 2022 and surged 733.33% in 2023, its largest moves.
• Candel Therapeutics' Other Accumulated Expenses stood at $334000.0 in 2021, then slumped by 85.63% to $48000.0 in 2022, then soared by 733.33% to $400000.0 in 2023, then rose by 16.0% to $464000.0 in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $464000.0, $55000.0, and $266000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison